^
    Back
    Association details:
    Biomarker:HER-2 expression
    Cancer:Gastroesophageal Junction Adenocarcinoma
    Drug:trastuzumab rezetecan (SHR-A1811) (Topoisomerase I inhibitor, HER2-targeted antibody-drug conjugate)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: C3 – Early Trials
    Source:
    ESMO 2023
    Title:

    656MO - The HER2-targeting ADC SHR-A1811 in HER2-expressing/mutated advanced non-breast solid tumors (STs): Results from the global phase I study

    Published date:
    10/16/2023
    Excerpt:
    SHR-A1811 had favorable antitumor activity and acceptable safety profile in heavily pretreated HER2-expressing/mutated advanced non-breast STs, including BTC, UC, GC/GEJA, and CRC.
    Trial ID:
    NCT04446260
    Evidence Level:
    Sensitive: C3 – Early Trials
    Source:
    ESMO 2023
    Title:

    684P - Phase I trial of SHR-A1811 in HER2-expressing advanced gastric cancer (GC) or gastroesophageal junction adenocarcinoma (GEJ) and colorectal cancer (CRC)

    Published date:
    10/16/2023
    Excerpt:
    The respective 6-mo PFS rates in GC/GEJ and in HER2-positve GC/GEJ at RP2D were 71.0% (95% CI 54.0-82.7) and 73.9% (95% CI 52.1-86.9); the corresponding rates in CRC were 75.6% (95% CI 57.9-86.6) and 85.5% (95% CI 65.6-94.3)….SHR-A1811 showed an acceptable safety profile and promising clinical activity in pts with HER2-expressing GC/GEJ and CRC.